Tegoprazan
- Generic Name
- Tegoprazan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O3
- CAS Number
- 942195-55-3
- Unique Ingredient Identifier
- W017G7IF4S
- Background
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. Tegoprazan’s strong and sustained ...
- Indication
用于治疗胃食管反流病、糜烂性食管炎及消化性溃疡等酸相关疾病。
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kim, Young Sung
- Target Recruit Count
- 174
- Registration Number
- NCT06743243
- Locations
- 🇰🇷
Korea University Medical Center, Guro Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 208
- Registration Number
- NCT06523764
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Target Recruit Count
- 160
- Registration Number
- NCT06318104
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Target Recruit Count
- 22
- Registration Number
- NCT05915871
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT05871398
- Locations
- 🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of
Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Yanqing Li
- Target Recruit Count
- 368
- Registration Number
- NCT05870683
- Locations
- 🇨🇳
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China
Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Wonkwang University Hospital
- Target Recruit Count
- 315
- Registration Number
- NCT05786807
- Locations
- 🇰🇷
Wonkwang University Hospital, Iksan, Jeollabuk, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 338
- Registration Number
- NCT05701540
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Zhang Xiaofeng,MD
- Target Recruit Count
- 100
- Registration Number
- NCT05647278
- Locations
- 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 561
- Registration Number
- NCT05577468
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.